We are seeking a highly motivated individual to join us as a SrTechnician. The successful candidate will work as part of the Analytical Development team of Cellectis in Paris (75) and will be dedicated to the development and validation of the analytical methods of next generation engineered CAR T-cells for adoptive immunotherapy. Within the team, the successful candidate will be in charge of the set up and execution of the experiments conducting to the validation of those analytical methods.
Hands-on expertise in development and validation of analytical procedures according to ICH Q2 R1.
Expertise in immunology techniques (Immuno-staining, ELISA, cytotoxicity test and Flow Cytometry).
Comfortable in a fast-paced small company environment with minimal direction and able to adjust workload based upon changing priorities
Good written and communication skills in French or English
Internal Number: 1234
Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com